Obesity helps drive half of new diabetes cases among Americans
By (0)
Researchers found that over nearly two decades, obesity contributed to anywhere from 30% to 53% of new Type 2 diabetes diagnoses among middle-aged and older Americans. Photo by TeroVesalainen/Pixabay
Obesity is the culprit in up to half of new diabetes cases among Americans each year, a new study estimates.
Researchers found that over nearly two decades, obesity contributed to anywhere from 30% to 53% of new Type 2 diabetes diagnoses among middle-aged and older Americans. That higher percentage was seen in recent years, as the prevalence of obesity rose nationally.
Advertisement It very clearly looks like trends in obesity and Type 2 diabetes run parallel to each other, said study author Dr. Sadiya Khan, an assistant professor at Northwestern University Feinberg School of Medicine in Chicago.
Credit: Gabriel Chamie
Universal HIV testing with linkage to treatment and prevention may be a promising approach to accelerate reductions in new infections in generalized epidemic settings, according to a study published February 9th, 2021 in the open-access journal
PLOS Medicine by Catherine Koss of the University of California, San Francisco, and colleagues.
Despite major gains in HIV testing and treatment, in 2019 there were 1.7 million new HIV infections, of which nearly 60% occurred in sub-Saharan Africa. Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine is highly effective for HIV prevention and could substantially reduce new HIV infections if offered alongside access to HIV testing and treatment. But little is known about the incidence of new HIV infections among PrEP users in settings with generalized HIV epidemics, particularly outside of selected risk groups. To address this knowledge gap, Koss and colleagues conducted communit
It very clearly looks like trends in obesity and type 2 diabetes run parallel to each other, said study author Dr. Sadiya Khan, an assistant professor at Northwestern University Feinberg School of Medicine in Chicago. It s well known that obesity is a major risk factor.
February 08, 2021
Early on in the COVID-19 pandemic, patient presentations and autopsy reports made it abundantly clear that abnormal coagulation and multiorgan clotting were key signatures of this disease. Interim results from an eagerly awaited international, multiplatform randomized trial were released recently, suggesting that moderately ill patients but not those who require ICU-level care can benefit from therapeutic-dose anticoagulation. Yet it remains unclear whether that’s the right approach to take as a routine strategy.
More of TCTMD s coverage on our COVID-19 hub.
That’s a critical question as the number of cases caused by more-infectious SARS-CoV-2 variants continue to mount around the world and asymptomatic spread continues. When can an anticoagulant help and who might it harm?